^
Association details:
| Biomarker: | FGFR2 overexpression |
|---|---|
| Cancer: | Lung Non-Small Cell Squamous Cancer |
| Drug: | rogaratinib (BAY 1163877) (FGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study.
Published date:
05/19/2021
Excerpt:
...determine clinical activity and safety of rogaratinib in patients with advanced SQCLC overexpressing tumor FGFR1-3 mRNA....Patients with metastatic SQCLC, previously treated with systemic treatment, overexpressing tumour FGFR mRNA were treated with rogaratinib...rogaratinib failed to improve PFS in patients overexpressing tumor FGFR mRNA.
DOI:
10.1200/JCO.2021.39.15_suppl.e21119
Trial ID:
